New hope for Tough-to-Treat blood cancer?
NCT ID NCT03031730
Summary
This early-stage study tested a new drug, KRT-232, added to a standard three-drug combination for multiple myeloma that has come back or stopped responding to treatment. The main goals were to find the safest dose and see how well the body handles the four-drug combination. It involved 35 adults whose cancer had progressed after prior therapies.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Huntsman Cancer Institute/University of Utah
Salt Lake City, Utah, 84112, United States
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
-
NYP/Weill Cornell Medical Center
New York, New York, 10065, United States
-
UCHealth University of Colorado Hospital
Aurora, Colorado, 80045, United States
-
University of California Davis Comprehensive Cancer Center
Sacramento, California, 95817, United States
-
University of Texas Health Science Center at San Antonio
San Antonio, Texas, 78229, United States
-
University of Texas at Austin
Austin, Texas, 78712, United States
Conditions
Explore the condition pages connected to this study.